ProQR Therapeutics logo
ProQR Therapeutics
PRQR | NASDAQ
Chart Builder DCF Calculator
$1.18
-$0.23 (-16.31%)
At close: Nov 16, 2026, 4:00 PM ET
$1.23
+$0.05 (+4.24%)
After-hours: Nov 16, 2026, 7:30 PM ET

ProQR Therapeutics Company Profile

Company profile explained

Company Profile

ProQR Therapeutics N.V. operates as a biopharmaceutical enterprise dedicated to discovering and developing RNA-based therapies designed to address genetic disorders. The company's pipeline includes two primary drug candidates in advanced clinical stages: Sepofarsen is currently in a Phase II/III clinical trial, known as the ILLUMINATE trial, targeting Leber Congenital Amaurosis 10 (LCA10). Ultevursen is also undergoing Phase II/III evaluation for the treatment of USH2A-mediated retinitis pigmentosa and Usher syndrome. Beyond its clinical programs, ProQR is actively developing its proprietary Axiomer RNA base-editing platform technology. Strategic collaborations are central to ProQR's strategy, evidenced by its licensing agreements with institutions such as Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center. Furthermore, a significant license and research partnership exists with Eli Lilly and Company, focused on the discovery, advancement, and commercialization of novel medicines for genetic conditions impacting the liver and nervous system. Established in 2012, ProQR Therapeutics N.V. maintains its corporate headquarters in Leiden, the Netherlands.

Key Executives

Name Position
Daniel Anton de Boer Founder, CEO & Executive Director
Dennis Hom Chief Financial Officer
Christopher Hart Chief Data & AI Officer
Cristina Lopez Lopez Chief Medical Officer
Gerard Platenburg Co-Founder, Chief Scientific Officer & Executive Director
Golnar Karimian Head of Hepatology
Sandra van der Kolk Junior Financial Controller
Sarah Cue Kiely Vice President of Investor Relations & Corporate Communications
Sheila Sponselee Chief People & Operations Officer

Latest SEC Filings

Date Type Title
Oct 30, 2026 6-K/A [Amend] Filing
Oct 28, 2026 6-K Filing
Sep 23, 2026 6-K Filing
Sep 09, 2026 6-K Filing
Aug 13, 2026 6-K Filing
Aug 13, 2026 6-K Filing
Aug 03, 2026 4 Filing
Jul 29, 2026 SC 13D/A [Amend] Filing
Jul 29, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Jul 24, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
View All SEC Filings ➞
ProQR Therapeutics
ProQR Therapeutics logo
Country Netherlands
IPO Date Sep 18, 2014
Industry Biotechnology
Sector Healthcare
Employees 166
CEO Daniel Anton de Boer

Contact Details

Zernikedreef 9 Leiden, ZH 2333 Ck Netherlands

Stock Details

Ticker Symbol PRQR
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001612940
CUSIP Number N71542109
ISIN Number NL0010872495
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.